Nontuberculous Mycobacteria Species in Patients with Concurrent COVID-19 and Mycobacterial Disease
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
The incidence of nontuberculous mycobacterial (NTM) diseases is increasing globally, with risk factors remaining poorly understood. COVID-19 may alter respiratory tract conditions affecting NTM colonization and infection patterns.
Objective
To evaluate species diversity of NTM isolated from patients with NTM-associated diseases with and without a history of COVID-19.
Methods
We analyzed 464 clinical NTM isolates from Russian patients stratified by COVID-19 status (COVID-19+, n=271; COVID-19−, n=193). Diagnosis verification followed ATS/ERS/ESCMID/IDSA Clinical Practice Guidelines. Species identification employed MALDI-TOF mass spectrometry and molecular techniques. Statistical analyses used chi-square and Fisher’s exact tests with 95% confidence intervals.
Results
Slowly growing species predominated in both groups (97.9% vs 98.2%, p>0.05). COVID-19 was associated with a significant 28% reduction in Mycobacterium avium complex (MAC) prevalence (94.8% vs 66.8%, p<0.05), primarily due to decreased M. avium isolation (80.3% vs 52.0%, p<0.05). Conversely, rare NTM species showed increased prevalence in COVID-19+ patients: M. kansasii complex (0% vs 8.1%, p<0.05), M. terrae complex (0% vs 3.3%, p<0.05), M. simiae complex (0.5% vs 7.0%, p<0.05), and unclassifiable species (2.6% vs 12.9%, p<0.05).
Conclusions
COVID-19 significantly alters the NTM species spectrum in patients with NTM-associated diseases, with reduced MAC prevalence and increased detection of rare NTM species. These findings highlight the importance of species-level identification and may require adaptation of diagnostic and therapeutic approaches in post-COVID patients.
